AGENUS INC Repayments of Debt
AGENUS INC (AGEN) reported Repayments of Debt of $462.00 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2024-03-14.
Discontinued › Cash Flow › Financing Activities
us-gaap:RepaymentsOfDebt · last filed 2024-03-14
- AGENUS INC repayments of debt for the quarter ending 2021-12-31 was $0.00, a 100.00% decline year-over-year.
- AGENUS INC repayments of debt for the quarter ending 2021-09-30 was $0.00, a 100.00% decline year-over-year.
- AGENUS INC repayments of debt for the quarter ending 2021-06-30 was $230.00K, a 54.00% decline year-over-year.
- AGENUS INC repayments of debt for the quarter ending 2021-03-31 was $232.00K, a 53.60% decline year-over-year.
- AGENUS INC repayments of debt for fiscal 2021 was $462.00K, a 68.40% decline from fiscal 2020.
- AGENUS INC repayments of debt for fiscal 2020 was $1.46M.
- AGENUS INC repayments of debt for fiscal 2018 was $161.85M.
- AGENUS INC repayments of debt for fiscal 2015 was $1.11M, a 66.67% decline from fiscal 2014.
| Period end | Repayments of Debt 3 month | Repayments of Debt 3 month as first filed | Repayments of Debt 6 month | Repayments of Debt 6 month as first filed | Repayments of Debt 9 month | Repayments of Debt 9 month as first filed | Repayments of Debt 12 month | Repayments of Debt 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $0.00 derived: sum of 2 quarters · filed 2024-03-14 | $230.00K derived: sum of 3 quarters · filed 2024-03-14 | $462.00K 10-K · filed 2024-03-14 | ||||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $230.00K derived: sum of 2 quarters · filed 2022-11-08 | $462.00K 10-Q · filed 2022-11-08 | $693.00K derived: sum of 4 quarters · filed 2023-03-16 | ||||
| 2021-06-30 | $230.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $462.00K 10-Q · filed 2022-08-09 | $693.00K derived: sum of 3 quarters · filed 2023-03-16 | $924.00K derived: sum of 4 quarters · filed 2023-03-16 | ||||
| 2021-03-31 | $232.00K 10-Q · filed 2022-05-10 | $463.00K derived: sum of 2 quarters · filed 2023-03-16 | $694.00K derived: sum of 3 quarters · filed 2023-03-16 | $1.19M derived: sum of 4 quarters · filed 2023-03-16 | ||||
| 2020-12-31 | $231.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $462.00K derived: sum of 2 quarters · filed 2023-03-16 | $962.00K derived: sum of 3 quarters · filed 2023-03-16 | $1.46M 10-K · filed 2023-03-16 | ||||
| 2020-09-30 | $231.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $731.00K derived: sum of 2 quarters · filed 2021-11-09 | $1.23M 10-Q · filed 2021-11-09 | |||||
| 2020-06-30 | $500.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $1.00M 10-Q · filed 2021-08-09 | ||||||
| 2020-03-31 | $500.00K 10-Q · filed 2021-05-07 | |||||||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | $0.00 derived: sum of 2 quarters · filed 2021-03-16 | $0.00 derived: sum of 3 quarters · filed 2021-03-16 | $161.85M 10-K · filed 2021-03-16 | $161.85M 10-K · filed 2019-03-18 | |||
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $0.00 derived: sum of 2 quarters · filed 2019-11-07 | $161.85M 10-Q · filed 2019-11-07 | $161.85M 10-Q · filed 2018-11-07 | ||||
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | $161.85M 10-Q · filed 2019-08-09 | $161.85M 10-Q · filed 2018-08-09 | |||||
| 2018-03-31 | $161.85M 10-Q · filed 2019-05-10 | $161.85M 10-Q · filed 2018-05-10 | ||||||
| 2016-03-31 | $0.00 10-Q · filed 2016-05-09 | -$1.00 derived: sum of 2 quarters · filed 2018-03-16 | -$1.00 derived: sum of 3 quarters · filed 2018-03-16 | $277.78K derived: sum of 4 quarters · filed 2018-03-16 | ||||
| 2015-12-31 | -$1.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16 | -$1.00 derived: sum of 2 quarters · filed 2018-03-16 | $277.78K derived: sum of 3 quarters · filed 2018-03-16 | $1.11M 10-K · filed 2018-03-16 | ||||
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $277.78K derived: sum of 2 quarters · filed 2016-11-09 | $1.11M 10-Q · filed 2016-11-09 | $1.94M derived: sum of 4 quarters · filed 2017-03-16 | ||||
| 2015-06-30 | $277.78K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $1.11M 10-Q · filed 2016-08-04 | $1.94M derived: sum of 3 quarters · filed 2017-03-16 | |||||
| 2015-03-31 | $833.33K 10-Q · filed 2016-05-09 | $1.67M derived: sum of 2 quarters · filed 2017-03-16 | ||||||
| 2014-12-31 | $833.33K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $3.33M 10-K · filed 2017-03-16 | ||||||
| 2014-09-30 | $2.50M 10-Q · filed 2015-11-04 | |||||||
| 2013-12-31 | $555.56K 10-K · filed 2016-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |